Phosphatidylserine Blockade Limits Systemic Dissemination of Leishmania Amazonensis Amastigotes.

Authors

Arieli Bernardo Portugal, Suzana Passos Chaves, Renato Augusto DaMatta, João Luiz Mendes Wanderley

Published in

Journal of immunology research. Volume 2026. Issue 1. Pages e4561938.

Abstract

Leishmania amazonensis is associated with cases of cutaneous, disseminated, diffuse, mucosal, and visceral leishmaniasis (VL). The mechanisms underlying its ability to persist and spread after the initial clinical cure are unclear, although intrinsic characteristics of the parasite and the host may be involved. Phosphatidylserine (PS) is a pathogenic factor in both experimental models and in patients. It is related to macrophage infection, regulation of inflammatory and immune responses, and the extent and severity of the clinical outcomes of the disease. In a murine model of systemic infection, treatment with PS-targeting antagonist antibodies significantly reduced parasite burden in the spleen. In parallel, the number and size of disseminated skin lesions were consistently reduced. These effects correlated with a substantial decrease in interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) production by splenocytes stimulated with leishmanial antigens, indicating a reversal of the regulatory immune profile commonly associated with chronic infection. These findings support a critical role for PS in the dissemination and visceralization of Leishmania amazonensis, highlighting its contribution to immune evasion and the pathogenesis of severe disease forms.

PMID:
42895239
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.